Introduction
Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
Uses
Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin used to treat female infertility by inducing ovulation.
For the treatment of female infertility
Associated Conditions
Pharmacodynamics
Choriogonadotropin alfa is used to treat female infertility, Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.
Mechanism of Action
Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
Absorption
The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
Volume of Distribution
- 5.9 ± 1.0 L
Route of Elimination
One-tenth of the dose is excreted in the urine.
Half Life
The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).
Clearance
- 0.29 +/- 0.04 L/h [healthy down-regulated females]
Food Interactions
No interactions found.
Dosage
Infertile Women Undergoing Ovulation Induction (OI): Choriogonadotropin Alfa PreFilled Syringe should not be administered until adequate follicular development is indicated by serum estradiol and vaginal ultrasonography. Choriogonadotropin Alfa PreFilled Syringe 250 μg should be administered one day following the last dose of the follicle stimulating agent. Choriogonadotropin Alfa PreFilled Syringe administration should be withheld in situations where there is an excessive ovarian response, as evidenced by multiple follicular development, clinically significant ovarian enlargement or excessive estradiol production.
